Erdafitinib for locally advanced or metastatic urothelial carcinoma.
作者信息
Siefker-Radtke Arlene O, Loriot Yohann
机构信息
Department of Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Department of Cancer Medicine INSERM U981 Gustave Roussy Université Paris-Saclay Villejuif, France.
出版信息
Am J Health Syst Pharm. 2022 May 24;79(11):824-825. doi: 10.1093/ajhp/zxac030.
Abstract
摘要
相似文献
1
Erdafitinib for locally advanced or metastatic urothelial carcinoma.厄达替尼用于局部晚期或转移性尿路上皮癌。
Am J Health Syst Pharm. 2022 May 24;79(11):824-825. doi: 10.1093/ajhp/zxac030.
2
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.厄达替尼治疗局部晚期或转移性尿路上皮癌患者的疗效和安全性：一项 2 期研究的长期随访结果。
Lancet Oncol. 2022 Feb;23(2):248-258. doi: 10.1016/S1470-2045(21)00660-4. Epub 2022 Jan 11.
3
Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand.厄达替尼作为转移性尿路上皮癌治疗选择的临床应用概述：我们处于何种地位。
Expert Rev Clin Pharmacol. 2020 Oct;13(10):1139-1146. doi: 10.1080/17512433.2020.1823830. Epub 2020 Oct 6.
4
Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain genetic alterations.厄达替尼治疗存在某些遗传改变的局部晚期/转移性尿路上皮癌。
Future Oncol. 2022 Jun;18(19):2455-2464. doi: 10.2217/fon-2021-1151. Epub 2022 Apr 7.
5
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.厄达替尼与帕博利珠单抗治疗既往治疗的伴有特定 FGFR 改变的局部晚期或转移性尿路上皮癌患者的随机 III 期 THOR 试验：队列 2。
Ann Oncol. 2024 Jan;35(1):107-117. doi: 10.1016/j.annonc.2023.10.003. Epub 2023 Oct 21.
6
Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer.厄达替尼：一种用于治疗 FGFR 突变型尿路上皮癌的新型疗法。
Am J Health Syst Pharm. 2020 Feb 19;77(5):346-351. doi: 10.1093/ajhp/zxz329.
7
Erdafitinib for the treatment of metastatic bladder cancer.厄达替尼治疗转移性膀胱癌。
Expert Rev Clin Pharmacol. 2020 Jan;13(1):1-6. doi: 10.1080/17512433.2020.1702025. Epub 2019 Dec 22.
8
Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma.在局部晚期或转移性尿路上皮癌患者中评估厄达替尼的暴露-反应关系。
Cancer Chemother Pharmacol. 2022 Feb;89(2):151-164. doi: 10.1007/s00280-021-04381-4. Epub 2022 Jan 3.
9
Re: Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.关于：厄达替尼或化疗用于晚期或转移性尿路上皮癌
Eur Urol. 2024 Jun;85(6):591-592. doi: 10.1016/j.eururo.2024.02.020. Epub 2024 Mar 26.
10
Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma.厄达替尼：转移性尿路上皮癌的新型先进治疗策略。
Anticancer Agents Med Chem. 2021;21(18):2478-2486. doi: 10.2174/1871520621666210121093852.
本文引用的文献
1
Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer.厄达替尼：一种用于治疗 FGFR 突变型尿路上皮癌的新型疗法。
Am J Health Syst Pharm. 2020 Feb 19;77(5):346-351. doi: 10.1093/ajhp/zxz329.
2
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.厄达替尼治疗局部晚期或转移性尿路上皮癌。
N Engl J Med. 2019 Jul 25;381(4):338-348. doi: 10.1056/NEJMoa1817323.
3
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.多中心 I 期临床试验 Erdafitinib（JNJ-42756493），口服泛成纤维细胞生长因子受体抑制剂，治疗晚期或难治性实体瘤患者。
Clin Cancer Res. 2019 Aug 15;25(16):4888-4897. doi: 10.1158/1078-0432.CCR-18-3334. Epub 2019 May 14.
Zotero 插件